Influence of two different perfusion systems on inflammatory response in pediatric heart surgery

Annals of Thoracic Surgery

Volumn 75, Issue 3, 2003, Pages 919-925

  Jensen, Eva ^a,b   Andréasson, Svenerik ^a   Bengtsson, Anders ^a   Berggren, Håkan ^a   Ekroth, Rolf ^a   Lindholm, Lena ^a   Ouchterlony, John ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b SU ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4D; COMPLEMENT MEMBRANE ATTACK COMPLEX; ELASTASE; HEPARIN; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONGENITAL HEART MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGRANULATION; DISEASE COURSE; ENZYME RELEASE; FEMALE; HEART PERFUSION; HUMAN; INFANT; INFLAMMATION; MALE; MATERIAL COATING; PEDIATRIC SURGERY; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUMP; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; CARDIOPULMONARY BYPASS; CHILD; CHILD, PRESCHOOL; COATED MATERIALS, BIOCOMPATIBLE; COMPLEMENT ACTIVATION; EQUIPMENT DESIGN; FEMALE; HEART DEFECTS, CONGENITAL; HEPARIN; HUMANS; INFANT; INFLAMMATION MEDIATORS; INTERLEUKIN-6; INTERLEUKIN-8; LEUKOCYTE ELASTASE; MALE; POSTOPERATIVE COMPLICATIONS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037337490     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(02)04501-0     Document Type: Article

References (20)

1. Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass. Mechanisms involved and possible therapeutic strategies. Chest 1997;112:676-92.
2. Boyle EM, Pohlman TH, Johnson MC, Verrier ED. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg 1997;63:277-84.
3. Brix-Christensen V. The systemic inflammatory response after cardiac surgery with cardiopulmonary bypass in children. Acta Anaestesiol Scand 2001;45:671-9.
4. Jensen E, Bengtsson A, Berggren H, Ekroth R, Andréasson S. Clinical variables and pro-inflammatory activation in paediatric heart surgery. Scand Cardiovasc J 2001;35:201-6.
5. Steinberg BM, Grossi EA, Schwartz DS, et al. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann Thorac Surg 1995;60:525-9.
6. Fosse E, Moen O, Johnson E, et al. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1994;58:472-7.
7. Grossi EA, Kallenbach K, Chau S, et al. Impact of heparin bonding on pediatric cardiopulmonary bypass: a prospective randomized study. Ann Thorac Surg 2000;70:191-6.
8. Olsson C, Siegbahn A, Henze A, et al. Heparin-coated cardiopulmonary bypass circuits reduce circulating complement factors, and interleukin-6 in peadiatric heart surgery. Scand Cardiovasc J 2000;34:33-40.
9. Moen O, Fosse E, Bråten J, et al. Roller and centrifugal pumps compared in vitro with regard to haemolysis, granulocyte and complement activation. Perfusion 1994;9:109-17.
10. Moen O, Fosse E, Bråten J, et al. Differences in blood activation related to roller/centrifugal pumps and heparin-coated/uncoated surfaces in cardiopulmonary bypass model circuit. Perfusion 1996;11:113-23.
11. Wheeldon DR, Bethune DW, Gill RD. Vortex pumping for routine cardiac surgery: a comparative study. Perfusion 1990;5:135-43.
12. Nishida H, Aomi S, Tomizawa Y, et al. Comparative study of biocompatibility between the open circuit and closed circuit in cardiopulmonary bypass. Artific Organs 1999;23:547-51.
13. Elliot M. Ultrafiltration and modified ultrafiltration in pediatric open heart operations. Ann Thorac Surg 1993;56:1518-22.
14. Aashraf S, Tian Y, Cowan D, Entress A, Martin PG, Watterson KG. Release of proinflammatory cytokines during pediatric cardiopulmonary bypass: Heparin-bonded versus non-bonded oxygenators. Ann Thorac Surg 1997;64:1790-4.
15. Kagisaki K, Masai T, Kadoba K, et al. Biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass. Artific Organs 1997;21:836-40.
16. Ozawa T, Yoshihara K, Koyama N, Watanabe Y, Shiono N, Takanashi Y. Clinical efficacy of heparin-bonded bypass circuits related to cytokine responses in children. Ann Thorac Surg 2000;69:584-90.
17. Defraigne JO, Pincemail J, Larbuisson R, Blaffart F, Limet R. Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration. Ann Thorac Surg 2000;69:1084-91.
18. Horton SB, Butt WW, Mullaly RJ, et al. IL-6 and IL-8 levels after cardiopulmonary bypass are not affected by surface coating. Ann Thorac Surg 1999;68:1751-5.
19. Ashraf S, Tian Y, Cowan D, et al. Proinflammatory cytokine release during pediatric cardiopulmonary bypass: influence of centrifugal and roller pumps. J Cardiothorac Vasc Anesth 1997;11:718-22.
20. Schreurs HH, Wijers MJ, Gu YJ, et al. Heparin-coated bypass circuits, effects on inflammatory response in pediatric cardiac operations. Ann Thorac Surg 1998;66:166-71.